CA2721088A1 - Methods and compositions for accelerating the generation of regulatory t cells ex vivo - Google Patents

Methods and compositions for accelerating the generation of regulatory t cells ex vivo Download PDF

Info

Publication number
CA2721088A1
CA2721088A1 CA2721088A CA2721088A CA2721088A1 CA 2721088 A1 CA2721088 A1 CA 2721088A1 CA 2721088 A CA2721088 A CA 2721088A CA 2721088 A CA2721088 A CA 2721088A CA 2721088 A1 CA2721088 A1 CA 2721088A1
Authority
CA
Canada
Prior art keywords
cells
regulatory
tgf
cell
azacytidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2721088A
Other languages
English (en)
French (fr)
Inventor
David A. Horwitz
J. Dixon Gray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California
Original Assignee
University of Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California filed Critical University of Southern California
Publication of CA2721088A1 publication Critical patent/CA2721088A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2721088A 2008-04-11 2009-04-10 Methods and compositions for accelerating the generation of regulatory t cells ex vivo Abandoned CA2721088A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4430608P 2008-04-11 2008-04-11
US61/044,306 2008-04-11
PCT/US2009/040190 WO2009126877A2 (en) 2008-04-11 2009-04-10 Methods and compositions for accelerating the generation of regulatory tcells ex vivo

Publications (1)

Publication Number Publication Date
CA2721088A1 true CA2721088A1 (en) 2009-10-15

Family

ID=40853828

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2721088A Abandoned CA2721088A1 (en) 2008-04-11 2009-04-10 Methods and compositions for accelerating the generation of regulatory t cells ex vivo

Country Status (7)

Country Link
US (1) US20090257988A1 (enExample)
EP (1) EP2281031A2 (enExample)
JP (1) JP2011519271A (enExample)
CN (1) CN102066557A (enExample)
AU (1) AU2009234210A1 (enExample)
CA (1) CA2721088A1 (enExample)
WO (1) WO2009126877A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155477A1 (en) 2008-06-19 2009-12-23 The Trustees Of The University Of Pennsylvania Inducible regulatory t-cell generation for hematopoietic transplants
US20100291117A1 (en) * 2009-05-18 2010-11-18 Tinghua Cao Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases
CN102971416B (zh) * 2010-04-22 2018-03-30 南加州大学 用于扩增和稳定天然调节性t细胞的方法和组合物
CN102321580A (zh) * 2011-08-23 2012-01-18 郑颂国 一种治疗自体自身免疫性疾病的调节t细胞及其制备方法
EP2968565A2 (en) 2013-03-14 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
MX2016009306A (es) * 2014-01-17 2017-04-10 Dbv Tech Reequilibrado inmunologico epicutaneo.
CN105597090B (zh) * 2014-11-14 2022-08-23 中国科学院上海营养与健康研究所 一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用
US10905706B2 (en) 2015-01-08 2021-02-02 The Johns Hopkins University Compositions and methods to accelerate resolution of acute lung inflammation
WO2017066561A2 (en) * 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
CN108463547A (zh) * 2015-10-28 2018-08-28 生命技术股份公司 通过改变细胞表面信号和信号比选择性扩增不同的t细胞亚群
EP3551749B1 (en) 2016-12-07 2023-09-27 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells
JP7142846B2 (ja) 2017-01-30 2022-09-28 国立大学法人京都大学 新規化合物及び制御性ｔ細胞の製造方法
CN108060129A (zh) * 2017-12-11 2018-05-22 上海药明生物技术有限公司 调节性t细胞体外扩增方法
US11975024B2 (en) * 2017-12-19 2024-05-07 Musc Foundation For Research Development T regulatory (Treg) cell transplantation in osteogenesis imperfecta (OI)
EP3842522B1 (en) 2018-08-22 2025-10-15 The University of Osaka Method for producing regulatory t cells
US20210290742A1 (en) * 2018-09-27 2021-09-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of using lysine deacetylase (kdac) inhibition to generate antigen specific memory t cell responses for durable immunotherapy
JP2023527459A (ja) * 2020-06-01 2023-06-28 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 誘導性制御性ｔ細胞、その生成方法及び使用
GB202008957D0 (en) * 2020-06-12 2020-07-29 Autolus Ltd Culture medium
CN113502265B (zh) * 2021-05-25 2024-05-28 昭泰英基生物医药（香港）有限公司 将t细胞重编程为类nk细胞的诱导剂及其应用
CN119592507A (zh) * 2024-12-03 2025-03-11 哈尔滨优莱福生物科技有限公司 一种人外周血调节性t细胞的体外扩增试剂盒及其使用方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157057A1 (en) * 1999-05-05 2003-08-21 Horwitz David A. Methods for the induction of professional and cytokine-producing regulatory T cells
US20030147865A1 (en) * 2002-02-07 2003-08-07 Benoit Salomon Cell therapy using immunoregulatory T-cells
US20100061984A1 (en) * 2006-01-20 2010-03-11 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
ATE508207T1 (de) * 2006-02-28 2011-05-15 Charite Universitaetsmedizin Nachweis und qualitätskontrolle von regulator-t- zellen mittels dna-methylierungsanalyse des foxp3-gens
JP2010531138A (ja) * 2007-06-13 2010-09-24 ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー 制御性ｔ細胞ならびに同製造および使用方法

Also Published As

Publication number Publication date
AU2009234210A1 (en) 2009-10-15
EP2281031A2 (en) 2011-02-09
AU2009234210A2 (en) 2010-12-16
US20090257988A1 (en) 2009-10-15
CN102066557A (zh) 2011-05-18
JP2011519271A (ja) 2011-07-07
WO2009126877A2 (en) 2009-10-15
WO2009126877A3 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
US20090257988A1 (en) Methods and compositions for accelerating the generation of regulatory t cells ex vivo
KR101301923B1 (ko) 인간 혈액 유래의 ｃｄ4＋ｃｄ25＋ 조절성 ｔ 세포
US20230137331A1 (en) Activation and Expansion of T Cell Subsets Using Biocompatible Solid Substrates with Tunable Rigidity
Bharat et al. CD4+ 25+ regulatory T cells limit Th1‐autoimmunity by inducing IL‐10 producing T cells following human lung transplantation
ES2686593T3 (es) Expresión de CD127 que correlaciona inversamente con FoxP3 y la función supresora de Treg CD4+
JP7254128B2 (ja) ＣＤ８＋ＣＤ４５ＲＣｌｏｗ Ｔｒｅｇの新しい亜集団およびその使用
TWI846668B (zh) 高活性nk細胞及其利用
US20080175823A1 (en) Use of Cytokines and Mitogens to Inhibit Pathological Immune Responses
JP6068432B2 (ja) 治療における調節性ｔ細胞の使用方法
RU2627445C2 (ru) Способы идентификации, выделения, истощения и обогащения популяций tr1 клеток, популяции tr1 клеток, фармацевтические композиции, способ мониторинга эффекта терапии
KR20130093083A (ko) Il-13 생산 tr1-유사 세포 및 그의 용도
JP4132013B2 (ja) 病的免疫応答を抑制するサイトカインおよびマイトジェンの使用
WO2022122961A1 (en) Use of mait cells for controlling graft versus host disease
CN102971416B (zh) 用于扩增和稳定天然调节性t细胞的方法和组合物
WO2006111986A1 (en) Method for the detection and the isolation of immunosuppressive regulatory t cells and uses thereof
Wendering Regulatory T cells in adoptive immunotherapy: from subset characterization to functional testing
Halliday CD4 regulatory T cells: their requirement for CD80 and CD86 costimulation and their role in autoimmune hepatitis
Wendering DOCTOR OF PHILOSOPHY (PhD)

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130410